Skip to main content
SpringerLink
Log in

Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and Objective

Linifanib is a multi-targeted receptor tyrosine kinase inhibitor, which can inhibit members of the vascular endothelial growth factor and platelet-derived growth factor receptor families. The objective of this analysis was to characterize the population pharmacokinetics of linifanib in cancer patients.

Methods

We pooled 7,351 linifanib plasma concentrations from 1,010 cancer patients enrolled in 13 clinical studies. Population pharmacokinetic modelling was performed using NONMEM version 7.2. The covariates that were screened included the cancer type, co-medications, creatinine clearance, formulation, fed status, liver function markers (bilirubin, blood urea nitrogen [BUN], aspartate aminotransferase [AST], alanine aminotransferase [ALT]), albumin, age, sex, race, body weight, surface area and body mass index.

Results

A two-compartment model with first-order absorption and disposition best described linifanib pharmacokinetics. An increase in body weight was associated with less than proportional increases in volumes of distribution. Subjects with hepatocellular carcinoma and renal cell carcinoma were estimated to have 63 and 86 % larger volumes of distribution, respectively, than subjects with the other cancer types. Females had 25 % slower oral clearance (CL/F) than males, while subjects with colorectal cancer had 41 % faster CL/F than other subjects. For linifanib bioavailability, subjects with refractory acute myeloid leukaemia or myelodysplastic syndrome had 43 % lower bioavailability, evening doses were associated with 27 % lower bioavailability than morning doses, and administration of linifanib under fed conditions decreased the bioavailability by 14 %. Finally, the oral solution formulation showed two-fold faster absorption than the tablet formulations.

Conclusion

The use of mixed-effects modelling allowed robust assessment of the impact of the concomitant effects of body size, different cancer types, formulation, diurnal variation, sex and food on linifanib pharmacokinetics. The developed population pharmacokinetic model describes linifanib concentrations adequately and can be used to conduct simulations or to evaluate the linifanib exposure–response relationship.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.

    Article  PubMed  CAS  Google Scholar 

  2. Zetter P, Bruce R. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49(1):407–24.

    Article  PubMed  CAS  Google Scholar 

  3. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–80.

    Article  PubMed  CAS  Google Scholar 

  4. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103(2):159.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–60.

    Article  PubMed  CAS  Google Scholar 

  6. Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol. 2006;8(2):77–82.

    Article  PubMed  CAS  Google Scholar 

  7. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14(3):285.

    PubMed  Google Scholar 

  8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  PubMed  CAS  Google Scholar 

  9. Reck M, Von Pawel J, Zatloukal Pv, et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  PubMed  CAS  Google Scholar 

  11. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18(2):338–40.

    PubMed  CAS  Google Scholar 

  12. Dai Y, Hartandi K, Ji Z, et al. Discovery of N-(4-(3-amino-1 H-indazol-4-yl) phenyl)-N′-(2-fluoro-5-methylphenyl) urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 2007;50(7):1584–97.

    Article  PubMed  CAS  Google Scholar 

  13. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006;5(4):995–1006.

    Article  PubMed  CAS  Google Scholar 

  14. Linifanib. Drugs R D. 2010;10(2):111–22.

  15. Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119(2):380–7.

    Article  PubMed  CAS  Google Scholar 

  16. Asahina H, Tamura Y, Nokihara H, et al. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2012;69(6):1477–86.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Wong CI, Koh TS, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol. 2009;27(28):4718–26.

    Article  PubMed  CAS  Google Scholar 

  18. Steinberg J, Tan E, Wei-Peng Y. Preliminary analysis of ABT-869 safety, pharmacokinetics and efficacy in three phase 2 solid tumor studies [abstract no. 477P]. 33rd Congress of the European Society for Medical Oncology; Stockholm; 12–16 Sep 2008.

  19. Humerickhouse R, Gupta N, Goh B. Phase 1 comparison of pharmacokientics, safety and efficacy with low versus high doses of ABT-869 in refractory solid tumors [abstract no. 476P]. 33rd Congress of the European Society for Medical Oncology; Stockholm; 12–16 Sep 2008.

  20. Wang ES, Yee K, Koh LP, et al. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma. 2012;53(8):1543–51.

    Article  PubMed  CAS  Google Scholar 

  21. Gupta N, Yan Z, LoRusso P, Ricker J, Carlson D, Pradhan R. Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib. Mol Cancer Ther. 2009;8(12 Suppl):B53.

    Google Scholar 

  22. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Tan EH, Goss GD, Salgia R, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(8):1418–25.

    Article  PubMed  Google Scholar 

  24. Tannir NM, Wong YN, Kollmannsberger CK, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011;47(18):2706–14.

    Article  PubMed  CAS  Google Scholar 

  25. Etienne-Grimaldi M, Cardot J, François E, et al. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Clin Pharmacol Ther. 2007;83(3):413–5.

    Article  PubMed  CAS  Google Scholar 

  26. Hassan M, Öberg G, Bekassy A, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28(2):130–4.

    Article  PubMed  CAS  Google Scholar 

  27. Koren G, Langevin AM, Olivieri N, Giesbrecht E, Zipursky A, Greenberg M. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. Arch Pediatr Adolesc Med. 1990;144(10):1135.

    Article  CAS  Google Scholar 

  28. Muggia FM, Wu X, Spicer D, et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res. 1996;2(9):1461–7.

    PubMed  CAS  Google Scholar 

  29. Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of high-dose busulfan in children. Cancer Res. 1993;53(7):1534–7.

    PubMed  CAS  Google Scholar 

  30. Metzger G, Massari C, Etienne M-C, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther. 1994;56(2):190–201.

    Article  PubMed  CAS  Google Scholar 

  31. Petit E, Milano G, Lévi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988;48(6):1676–9.

    PubMed  CAS  Google Scholar 

  32. Squalli A, Oustrin J, Houin G. Clinical chronopharmacokinetics of doxorubicin (DXR). Annu Rev Chronopharmacol. 1989;5:393–6.

    Google Scholar 

  33. Lévi F. Circadian rhythms in 5-fluorouracil pharmacology and therapeutic applications. In: Rustum YM. Fluoropyrimidines in cancer therapy. Totowa: Humana Press, 2003. p. 107–28.

  34. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377–421.

    Article  PubMed  CAS  Google Scholar 

  35. Zhang C, Denti P, Decloedt E, et al. Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol. 2012;73(5):758–67.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  36. Iwahori T, Takeuchi H, Matsuno N, et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc. 2005;37:1739–40.

    Google Scholar 

  37. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol. 1999;51(8):887–90.

    Article  PubMed  CAS  Google Scholar 

  38. Belanger P. Chronobiological variation in the hepatic elimination of drugs and toxic chemical agents. Annu Rev Chronopharmacol. 1988;4:1–46.

    CAS  Google Scholar 

  39. Radzialowski FM, Bousquet WF. Daily rhythmic variation in hepatic drug metabolism in the rat and mouse. J Pharmacol Exp Ther. 1968;163(1):229–38.

    PubMed  CAS  Google Scholar 

  40. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006;4(1):25–36.

    Article  PubMed  CAS  Google Scholar 

  41. Lu J-F, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006;80(2):136–45.

    Article  PubMed  CAS  Google Scholar 

  42. Li J, Karlsson MO, Brahmer J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006;98(23):1714–23.

    Article  PubMed  CAS  Google Scholar 

  43. Bow EJ, Kilpartick MG, Scott BA, Clinich JJ, Cheang MS. Acute myeloid leukemia in Manitoba. Cancer. 1994;74(1):52–60.

    Article  PubMed  CAS  Google Scholar 

  44. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced d-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997;15(6):2254–61.

    PubMed  CAS  Google Scholar 

  45. Johnson E, MacGowan A, Potter M, et al. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother. 1990;25(5):837–42.

    Article  PubMed  CAS  Google Scholar 

  46. Sitar DS, Aoki FY, Bow EJ. Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine. J Clin Pharmacol. 2008;48(8):995–8.

    Article  PubMed  CAS  Google Scholar 

  47. Bow E, Meddings J. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20(12):2087–92.

    Article  PubMed  CAS  Google Scholar 

  48. Klotz U. Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet. 1976;1(3):204–18.

    Article  PubMed  CAS  Google Scholar 

  49. Gupta N, Chiu Y, Toh H, et al. Preliminary pharmacokinetics and safety comparison of Child–Pugh A (CPA) vs Child–Pugh B (CPB) patients enrolled in a phase 2 study in hepatocellular carcinoma (HCC). Presented at Annals of Oncology; 2010.

  50. Frohna P, Lu J, Eppler S, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006;46(3):282–90.

    Article  PubMed  CAS  Google Scholar 

  51. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499–523.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of Interest

This study was sponsored by AbbVie Inc. AbbVie Inc. contributed to the study design; research; data interpretation; and writing, review and approval of the manuscript for publication. Ahmed Hamed Salem, Denise Koenig and Dawn Carlson are employees of AbbVie Inc.

Author information

Authors and Affiliations

  1. Clinical Development, AbbVie Inc., 1 North Waukegan Road, AP13A-3, Dept. R4PK, North Chicago, IL, 60064, USA

    Ahmed Hamed Salem, Denise Koenig & Dawn Carlson

  2. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

    Ahmed Hamed Salem

Authors
  1. Ahmed Hamed Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denise Koenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dawn Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Hamed Salem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salem, A.H., Koenig, D. & Carlson, D. Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients. Clin Pharmacokinet 53, 347–359 (2014). https://doi.org/10.1007/s40262-013-0121-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-013-0121-2

Keywords

Search

Navigation